Prasco® Selected as Eli Lilly and Company's Authorized Generics Partner

Prasco to market the Authorized Generic of Zyprexa and Zyprexa Zydis in the U.S.

CINCINNATI, Oct. 20, 2011 /PRNewswire/ -- Prasco Laboratories, announced today it has signed a marketing and distribution agreement with Eli Lilly and Company (NYSE: LLY) to market the Authorized Generic version of ZYPREXA® (olanzapine) Tablets and ZYPREXA® ZYDIS (olanzapine) Orally Disintegrating Tablets, in the U.S.

Prasco will begin distribution of both products upon the first ANDA entrant into the market.  Prasco will market all six strengths of Olanzapine Tablets 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg and 20 mg.  Olanzapine Orally Disintegrating Tablets will be available in 5 mg, 10 mg, 15 mg, and 20 mg strengths. The financial terms of the agreement were not disclosed.

"Prasco's passion to bring high quality, low cost prescription drugs to consumers continues to expand," said Prasco Chief Executive Officer E. Thomas Arington. "We are especially excited to welcome Eli Lilly and Company to our Prasco family of partners."

Prasco is established as the Authorized Generics company, having brought more Authorized Generics to market than any other company by offering generic products that are identical to the Brand product. "Prasco partnerships with brand companies offer alternatives for consumers and pharmacists that are specific and measurable. This is especially true with the Olanzapine launch through our new Lilly relationship," Arington concluded.  

Olanzapine Tablets are therapeutically equivalent and substitutable for the brand ZYPREXA.  Olanzapine Orally Disintegrating Tablets are therapeutically equivalent and substitutable for the brand ZYPREXA ZYDIS.  

For additional information about ZYPREXA and ZYPREXA ZYDIS, please see Full Prescribing Information including Box Warning at http://pi.lilly.com/us/zyprexa-pi.pdf and Medication Guide at http://pi.lilly.com/us/zyprexa-medguide.pdf.

About Prasco Laboratories - Prasco, the Authorized Generics company, is the privately held healthcare company located in Mason, Ohio, that specializes in Authorized Generics. Prasco Authorized Generics provide patients with the identical brand drug experience at a price that competes with generics. Prasco Authorized Generics also simplify interactions between pharmacists and consumers because they are identical to branded drugs. Moreover, Prasco Authorized Generics offer brand pharmaceutical companies a strategic lifecycle management solution.

Prasco sells its product line through the major distribution channels, and operates from a cGMP compliant, VAWD certified 160,000 sq. ft. office and distribution center including DEA-approved capabilities for Schedule II-V controlled drug products and cold-chain distribution. For more information, visit www.prasco.com.

For additional information about ZYPREXA and/or ZYPREXA ZYDIS, please contact:  Stefanie Prodouz, Manager, Lilly Bio-Medicines Communications | 317.224.5331.

SOURCE Prasco Laboratories

Suggested Articles

After Purdue’s record opioid settlement, more deals could be on the way. But that doesn’t mean all defendants are prepared to go quietly.

Now in their third quarter on the market, Gilead's own Epclusa and Harvoni generics have together grabbed more than 20% of the U.S. hep C market.

Purdue is seeking bankruptcy after inking a $10 billion-plus opioid settlement with thousands of cities and counties, plus two dozen states.